The PPI results show that the key targets for the treatment of insomnia by BX-YYR are FOS, AKT1, CASP3, TP53, VEGFA, etc. These key targets involve 897 BP, 84 MF and 39 CC, mainly including the regulation of G protein-coupled neurotransmitter receptor activity, serotonin binding, catecholamine binding, etc. In addition, they are associated with neuroactive ligand–receptor interactions, serotonin synapses, calcium signaling pathway, amphetamine addiction, dopaminergic synapses, apoptosis, cAMP signaling pathway and other KEGG signaling pathway modulation. Here, VEGFA is linked to insomnia.